GSK and Moderna end vaccine patent fight with cross-licenses—and no payments

The story

GSK and Moderna have ended their patent disputes over Moderna’s COVID-19 and respiratory-syncytial-virus vaccines through a cross-license that does not require either company to pay the other. Moderna disclosed the agreement in a November 6 filing with the U.S. Securities and Exchange Commission, providing an unusually clear financial fact while leaving most commercial terms confidential.

The agreement was signed on October 28 and settles all disputes then pending between the companies in the United States and Europe. Moderna’s filing says the parties granted patent cross-licenses in the field of infectious disease and are not obligated to make payments of any kind in connection with those licenses. That language removes a direct royalty or settlement-payment obligation under the disclosed deal; it does not reveal duration, geographic limits, sublicensing rights or product-specific carve-outs.

The U.S. litigation began in Delaware in October 2024. GSK accused Moderna’s Spikevax COVID-19 vaccine and mRESVIA RSV vaccine of infringing patents concerning lipid-mRNA vaccine formulation technology. The challenged systems use lipid nanoparticles to protect fragile messenger RNA and deliver it into cells. Reuters reported that the settlement also covers allegations involving Moderna’s newer mNEXSPIKE COVID-19 vaccine.

GSK had also pursued related actions in Europe, including Unified Patent Court proceedings involving liposomes and modified liposomes for RNA delivery, and later cases in Spanish commercial courts. The portfolio structure matters because a vaccine can implicate multiple layers of intellectual property: lipid composition, particle formulation, modified RNA, sequence design, manufacturing and disease-specific use. A license covering only one layer may not clear every other right needed to sell a product.

On November 6, the companies asked the Delaware court to dismiss GSK’s U.S. claims with prejudice, meaning those claims cannot simply be refiled. GSK told Reuters that the resolution provides clarity and lets both companies focus on patient innovation. The dismissal ends the cases; it does not mean a court found Moderna liable, upheld GSK’s patents or determined that any asserted claim was infringed.

That distinction is especially important because parts of the European patent landscape had already shifted. Proceedings concerning two GSK European patents had been affected by revocation decisions at the European Patent Office, while other issues remained contested. Settlement avoids the risk that continued litigation would further narrow one side’s portfolio or produce conflicting national and UPC outcomes. It also prevents the public from learning how a court would construe the disputed claims on a complete evidentiary record.

The zero-payment structure contrasts with Moderna’s separate 2026 resolution with Arbutus Biopharma and Genevant. That agreement involved a $950 million fixed payment and a license for lipid-nanoparticle technology, according to Roivant’s SEC filing. The difference does not establish that GSK’s patents were weaker or that Moderna’s were stronger. It shows that patent settlements reflect the parties’ entire bargaining positions, including counterclaims, competing portfolios, product pipelines and litigation risk.

The cross-license may have strategic value beyond the three vaccines named in the lawsuits. Both companies are developing infectious-disease products, and Moderna’s current portfolio includes influenza and combination respiratory vaccines. Because the public disclosure describes the licensed field broadly, the agreement could reduce future collision risk. But the companies have not published a patent schedule, so outside observers cannot determine which assets or pipeline products receive freedom to operate.

INNOVOX analysis: this is less a victory for one patent owner than a private clearing mechanism for overlapping innovation. Cross-licensing lets two large developers continue research and sales without waiting years for courts and patent offices to map every boundary. The cost is reduced public guidance. Smaller vaccine companies still cannot tell which claims survived scrutiny, what a comparable license should cost or where the protected technology actually begins and ends.

What to watch next is whether the settlement produces clean dismissals across every European forum and whether either company later discloses more detail in securities filings. GSK’s separate litigation against Pfizer and BioNTech remains active, while Moderna continues to face or pursue other disputes involving mRNA and delivery technology. Those cases—not this private cross-license—may eventually supply the precedential answers the sector still lacks.

INNOVOX analysis

The no-payment cross-license suggests that both companies valued freedom to operate and litigation certainty more than a public damages award or definitive ruling. It also preserves optionality across future infectious-disease products. For the wider mRNA sector, the result shows how overlapping platform rights can be cleared contractually while leaving the underlying boundaries of lipid-delivery patents unresolved for everyone else.

What to watch

Watch the dismissal of related European and Spanish proceedings, any later disclosure of geographic or product limits, and whether the cross-license reaches future combination vaccines. GSK’s separate case against Pfizer and BioNTech, plus Moderna’s other mRNA patent disputes, will continue testing the same crowded technology stack.